Brief by Shorts91 Newsdesk / 04:18pm on 08 Oct 2026,Thursday Health & Wellness
The Centre has capped trade margins at 30% of the Maximum Retail Price (MRP) for all non-scheduled anti-cancer medicines, aiming to make cancer treatment more affordable. The measure covers branded and generic, domestic and imported, patented and non-patented drugs. According to government sources, the move could reduce the MRPs of some cancer medicines by up to 70% and save patients around ₹2,500 crore annually. The decision follows concerns raised by the Supreme Court over large differences between retailer purchase prices and MRPs. The policy seeks to curb excessive mark-ups while maintaining medicine availability.
